Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Canagliflozin (Invokana; Janssen) improved renal outcomes and showed potential renal protective effects in patients with type 2 diabetes, who either have, or are at risk for, cardiovascular disease, according to findings from the CANVAS clinical trial program presented at the American Society of Nephrology Kidney Week 2017 Annual Meeting.
Compared to placebo, canagliflozin was associated with a reduced risk of renal disease progression, including significantly reducing urinary albumin excretion (18% lower in all participants; 34% lower in those with baseline microalbuminuria; 36% lower in those with baseline macroalbuminuria) and stabilizing estimated glomerular filtration rate (eGFR) (rate gradually increased with canagliflozin over 6.5 years compared to progressive decline with placebo).
In addition, canagliflozin reduced the rates of several pre-specified major renal composite endpoints (ie, end-stage renal disease, doubled serum creatinine, renal death) by up to 47% (HR: 0.53, 95% CI: 0.33–0.84). With regard to safety, there was no increase in renal adverse events (ie, acute kidney injury, hyperkalemia) with canagliflozin when compared to placebo.
“New data from the CANVAS Program clearly indicate better renal outcomes for people treated with canagliflozin, and suggest that this agent protects kidney function, in addition to providing previously presented cardiovascular benefits,” said Vlado Perkovic, MBBS, PhD, FASN, FRACP, Professor of Medicine, University of New South Wales Sydney, and Executive Director, The George Institute for Global Health.
Invokana, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, is approved by the Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
For more information visit Janssen.com.
